Actively Recruiting
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Led by Corvus Pharmaceuticals, Inc. · Updated on 2026-03-05
200
Participants Needed
1
Research Sites
82 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The main purpose of this study is to see how well different doses of soquelitinib work in participants with atopic dermatitis (AD) as compared to a placebo (pill with no medicine in it). To check this, the study doctors will examine participants' skin regularly to track how their AD changes during the study. The study doctors will see how safe soquelitinib is by tracking side effects among participants. They will also check "tolerability," which means how well the participants can handle soquelitinib and whether any potential side effects are manageable for them. To understand how well soquelitinib works, it will be compared with a placebo. Placebo is a substance that looks like soquelitinib but contains no active medicine in it. Participants will: * Take study treatment (soquelitinib or placebo) every day for 12 weeks * Visit the clinic for check-ups and tests every week for the first 2 weeks then every 2 weeks during the treatment period, and then return for follow-up visits 30, 60, and 90 days after the last dose of study treatment
CONDITIONS
Official Title
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older at screening
- Diagnosis of atopic dermatitis with symptoms starting at least 1 year before screening
- Moderate to severe disease at screening defined by EASI score of 16 or higher
- Body surface area affected of 10% or more
- Investigator Global Assessment score of 3 or higher
- Average itch severity score of 4 or higher over 7 days before randomization
- History of prior topical or systemic therapy for atopic dermatitis within 6 months before randomization
- Female participants must not be pregnant or breastfeeding and must either be of non-childbearing potential or agree to use effective birth control
You will not qualify if you...
- Other skin conditions that could interfere with evaluating atopic dermatitis
- Active skin infections requiring systemic treatment within 30 days before baseline
- Known immunodeficiency syndrome or recent serious infection needing treatment within 30 days before baseline
- History of immunosuppression not related to medication or significant medical conditions that could affect participation
- Unstable or uncontrolled illnesses such as cerebrocardiovascular, respiratory, gastrointestinal, endocrine, hematologic, or neurologic disorders that may affect safety or study assessments
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Corvus Clinical Trials
South San Francisco, California, United States, 94080
Actively Recruiting
Research Team
C
Corvus Clinical Trials
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here